Full text
Earnings transcript
Read the complete earnings call transcript.
REGN
Regeneron Pharmaceuticals, Inc.
$662.88
-13.35
(-1.97%)
| Exchange: | NASDAQ |
| Market Cap: | 68.291B |
| Shares Outstanding: | 15.364M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Leonard S. Schleifer | |||||
| Full Time Employees: | 15158 | |||||
| Address: |
| |||||
| Website: | https://www.regeneron.com |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 13,117,200 | 14,202,000 | 14,342,900 |
| Gross Profit | 10,872,700 | 12,231,500 | 12,242,200 |
| EBITDA | 4,693,300 | 5,318,000 | 5,818,200 |
| Operating Income | 4,348,600 | 3,990,700 | 3,577,900 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 33,080,200 | 37,759,400 | 40,558,700 |
| Total Liabilities | 7,107,100 | 8,405,800 | 2,747,600 |
| Total Stockholders Equity | 25,973,100 | 29,353,600 | 31,256,900 |
| Total Debt | 2,702,900 | 2,704,400 | 2,705,900 |
| Cash and Cash Equivalents | 2,730,000 | 2,488,200 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 4,594,000 | 4,420,500 | 4,978,900 |
| Capital Expenditure | -926,400 | -755,900 | -898,400 |
| Free Cash Flow | 3,667,600 | 3,664,600 | 4,080,500 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
| Net Change in Cash | -381,600 | -248,800 | 634,700 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 19,927,256.101 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 23,127,977.556 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 21,460,867.071 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 8,654,852.016 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 10,044,996.771 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 9,320,933.484 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 7,084,922.885 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 8,599,263.019 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 7,810,512.071 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 3,496,206.027 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 4,057,767.618 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 3,765,275.682 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 71.920 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 79.180 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 65.240 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 11 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 6 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: REGN demonstrates strong revenue and net income growth as reflected in recent income statements, underpinned by consistent operating cash flow and free cash flow generation. The freeCashFlowYieldTTM indicates a solid return on investment for shareholders.
- High Profitability Metrics: The company exhibits impressive grossProfitMarginTTM and netProfitMarginTTM, showcasing operational efficiency and a competitive edge within the biotechnology industry.
- Strong Balance Sheet: REGN maintains a healthy currentRatioTTM and quickRatioTTM, indicating good liquidity to cover short-term obligations. Additionally, a low debtToEquityRatioTTM reflects a conservative approach to leverage, reducing financial risk.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates REGN intrinsic value between $468.48 – $770.39 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about REGN valuation
Is Regeneron Pharmaceuticals, Inc. (REGN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Regeneron Pharmaceuticals, Inc. (REGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is REGN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether REGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is REGN’s P/E ratio?
You can see REGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for REGN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is REGN a good long-term investment?
Whether REGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
REGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.97
Trading Metrics:
| Open: | 669.95 | Previous Close: | 676.23 | |
| Day Low: | 661.39 | Day High: | 670.35 | |
| Year Low: | 541 | Year High: | 821.11 | |
| Price Avg 50: | 653.81 | Price Avg 200: | 700.73 | |
| Volume: | 729888 | Average Volume: | 992970 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeREGN full analysis
Welcome to MARKETSNAP’s SWOT analysis for Regeneron Pharmaceuticals, a heavyweight in the biotech space that many of you are likely already familiar with. If you’re invested in the health sector or just keeping an eye on innovative companies, you’ve probably heard of Regeneron, or REGN on the ticker. Today, we’re diving deep into what makes this company tick, breaking down its strengths, weaknesses, opportunities, and threats, all while keeping a long-term investor’s perspective in mind. Let’s unpack the latest developments,…
